Versant Venture Management, LLC
An institutional investment manager in San Francisco, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 12, 2026. SEC CIK 1560009.
- Reported value$162.6m
- Positions8
Holdings: 8 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE | Common Stock | 61225M102 | 77.0 | 47.3% | 3,180,780 | Unchanged | |
| Century Therapeutics, Inc.IPSC | Common Stock | 15673T100 | 29.8 | 18.3% | 12,166,109 | Unchanged | |
| Jade Biosciences, Inc.JBIO | Common Stock | 008064206 | 22.0 | 13.6% | 991,783 | Reduced−534,037 | |
| Lenz Therapeutics, Inc.LENZ | Common Stock | 52635N103 | 15.1 | 9.3% | 2,656,888 | Unchanged | |
| Contineum Therapeutics, Inc.CTNM | Common Stock | 21217B100 | 8.9 | 5.5% | 542,628 | Unchanged | |
| CRISPR Therapeutics AG | Common Shares | H17182108 | 8.1 | 5.0% | 148,831 | Unchanged | |
| Skye Bioscience, Inc. | Common Stock | 83086J200 | 1.4 | 0.9% | 2,007,704 | Unchanged | |
| Tempest Therapeutics, Inc. | Common Stock | 87978U108 | 0.3 | 0.2% | 269,772 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-347068 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.